Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 740859
                    [Title] => Novartis plans 2,000 jobs cuts despite profit rise
                    [Summary] => 
Swiss pharmaceutical giant Novartis AG said Tuesday it will cut 2,000 jobs as drug prices come under pressure from governments seeking to reduce health care budgets.
                    [DatePublished] => 2011-10-25 17:40:57
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 689454
                    [Title] => Reducing risk of MS disability progression
                    [Summary] => 
A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

GILENYA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 740859
                    [Title] => Novartis plans 2,000 jobs cuts despite profit rise
                    [Summary] => 
Swiss pharmaceutical giant Novartis AG said Tuesday it will cut 2,000 jobs as drug prices come under pressure from governments seeking to reduce health care budgets.
                    [DatePublished] => 2011-10-25 17:40:57
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 689454
                    [Title] => Reducing risk of MS disability progression
                    [Summary] => 
A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Novartis plans 2,000 jobs cuts despite profit rise

October 25, 2011 - 5:40pm

Swiss pharmaceutical giant Novartis AG said Tuesday it will cut 2,000 jobs as drug prices come under pressure from governments seeking to reduce health care budgets.

Reducing risk of MS disability progression

May 26, 2011 - 12:00am

A new analysis demonstrated that fingolimod reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.

Science and Environment